论文部分内容阅读
目的观察在不能耐受利福平的初治肺结核患者中加用左氧氟沙星对防止耐多药出现的临床效果。方法选取该院2014年4月-2016年3月收治的不能耐受利福平的肺结核初治患者76例,随机分为观察组和对照组各38例。对照组给予常规方案治疗,观察组在常规方案治疗的基础上加用0.4g/d的左氧氟沙星,观察2组患者治疗1、3、6个月后的痰液菌转阴情况,治疗过程中的不良反应发生情况及治疗6个月后的病灶吸收情况。结果观察组治疗1、3、6个月后痰液细菌检测转阴率均大于对照组,完全转阴时间均短于对照组,不良反应总发生率为55.26%低于对照组的89.47%,病灶吸收率为89.47%高于对照组的76.32%,差异均有统计学意义(P<0.05)。结论左氧氟沙星用于不能耐受利福平的初治肺结核患者具有防止耐多药、治疗效果佳的特点,值得临床应用和推广。
Objective To observe the clinical effect of levofloxacin on preventing the emergence of multi-drug resistance in newly diagnosed pulmonary tuberculosis patients who can not tolerate rifampicin. Methods 76 cases of newly diagnosed pulmonary tuberculosis patients who could not tolerate rifampin admitted from April 2014 to March 2016 in our hospital were randomly divided into observation group (38 cases) and control group (38 cases). The control group was given conventional regimen. The observation group was treated with 0.4g / d levofloxacin on the basis of routine regimen. The sputum negative bacteria were observed after 1, 3 and 6 months of treatment in both groups. During the treatment Adverse reactions occurred and the treatment of 6 months after the absorption of the lesion. Results In the observation group, the negative rates of sputum bacterial tests after 1, 3, and 6 months of treatment were significantly higher than those of the control group, and the complete negative conversion time was shorter than that of the control group. The overall incidence of adverse reactions was 55.26% lower than that of the control group (89.47% The absorption rate of lesions was 89.47% higher than that of the control group (76.32%), the differences were statistically significant (P <0.05). Conclusion Levofloxacin can not tolerate rifampin in patients with newly diagnosed tuberculosis has the characteristics of prevention of multi-drug resistance, good treatment effect, it is worth clinical application and promotion.